Peter A. Humphrey

Haoyue Zhang, Meera Chappidi, Erolcan Sayar et al.

Recent deep learning frameworks in histopathology, particularly multiple instance learning (MIL) combined with pathology foundational models (PFMs), have shown strong performance. However, PFMs exhibit limitations on certain cancer or specimen types due to domain shifts - these cancer types were rarely used for pretraining or specimens contain tissue-based artifacts rarely seen within the pretraining population. Such is the case for transurethral resection of bladder tumor (TURBT), which are essential for diagnosing muscle-invasive bladder cancer (MIBC), but contain fragmented tissue chips and electrocautery artifacts and were not widely used in publicly available PFMs. To address this, we propose a simple yet effective domain-adaptive self-supervised adaptor (DA-SSL) that realigns pretrained PFM features to the TURBT domain without fine-tuning the foundational model itself. We pilot this framework for predicting treatment response in TURBT, where histomorphological features are currently underutilized and identifying patients who will benefit from neoadjuvant chemotherapy (NAC) is challenging. In our multi-center study, DA-SSL achieved an AUC of 0.77+/-0.04 in five-fold cross-validation and an external test accuracy of 0.84, sensitivity of 0.71, and specificity of 0.91 using majority voting. Our results demonstrate that lightweight domain adaptation with self-supervision can effectively enhance PFM-based MIL pipelines for clinically challenging histopathology tasks. Code is Available at https://github.com/zhanghaoyue/DA_SSL_TURBT.

Peter Ström, Kimmo Kartasalo, Henrik Olsson et al.

Background: An increasing volume of prostate biopsies and a world-wide shortage of uro-pathologists puts a strain on pathology departments. Additionally, the high intra- and inter-observer variability in grading can result in over- and undertreatment of prostate cancer. Artificial intelligence (AI) methods may alleviate these problems by assisting pathologists to reduce workload and harmonize grading. Methods: We digitized 6,682 needle biopsies from 976 participants in the population based STHLM3 diagnostic study to train deep neural networks for assessing prostate biopsies. The networks were evaluated by predicting the presence, extent, and Gleason grade of malignant tissue for an independent test set comprising 1,631 biopsies from 245 men. We additionally evaluated grading performance on 87 biopsies individually graded by 23 experienced urological pathologists from the International Society of Urological Pathology. We assessed discriminatory performance by receiver operating characteristics (ROC) and tumor extent predictions by correlating predicted millimeter cancer length against measurements by the reporting pathologist. We quantified the concordance between grades assigned by the AI and the expert urological pathologists using Cohen's kappa. Results: The performance of the AI to detect and grade cancer in prostate needle biopsy samples was comparable to that of international experts in prostate pathology. The AI achieved an area under the ROC curve of 0.997 for distinguishing between benign and malignant biopsy cores, and 0.999 for distinguishing between men with or without prostate cancer. The correlation between millimeter cancer predicted by the AI and assigned by the reporting pathologist was 0.96. For assigning Gleason grades, the AI achieved an average pairwise kappa of 0.62. This was within the range of the corresponding values for the expert pathologists (0.60 to 0.73).